ArticleJournal of clinical medicine research2026
Usefulness of Blood Rheology as a Predictor of Primary Cardiovascular Disease Events in Patients With Stage G3 Chronic Kidney Disease.
Article in Journal of clinical medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several studies have highlighted that impairment of blood rheology plays a crucial role in the development of cardiovascular disease (CVD) and arteriosclerosis. However, the value of blood rheology as a potential predictor of the development of CVD in patients with chronic kidney disease (CKD) remains unknown. The objective of this prospective study was to investigate the utility of blood rheology using whole blood passage time (WBPT) as a predictor of primary CVD events in patients with stage G3 CKD, which is often encountered in daily practice. Methods: This study involved 417 outpatients with stage G3 CKD (male/female: 144/273) without history of CVD. WBPT was measured by microchannel array flow analyzer as a commercial device. Subsequently, the author evaluated the effectiveness of WBPT for the prediction of primary CVD events, which were defined as major adverse cardiovascular events (MACEs, i.e., cardiovascular death, nonfatal ischemic heart disease, and non-fatal ischemic stroke). Results: Patients were assigned into two groups according to the WBPT cut-off value, which was estimated by receiver operating characteristic curve analysis: low (group L, WBPT ≤ 74.3 s; n = 255) or high (group H, WBPT > 74.3 s; n = 162). During the median follow-up period of 76 months (range: 2-96 months), MACEs occurred in 74 patients (group L: n = 17 (6.7%) vs. group H: n = 57 (35.2%); P < 0.001, log-rank test). Multivariate Cox regression analysis revealed that patients in group H were at a significantly higher risk of developing MACEs than those in group L (hazard ratio: 3.89; 95% confidence interval: 2.12-7.10; P < 0.001). Conclusions: The present findings showed that impairment of blood rheology, determined using WBPT, is predictive of primary CVD events in patients with stage G3 CKD. Further large-scale studies are warranted to confirm whether various interventions can reduce the incidence of primary CVD events with improved WBPT in patients with stage G3 CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.